Lupin, Inc.

Lupin Atlantis Holdings Sa

Rajender Kumar Kamboj

Venkata Poornapragnacharyulu Palle

Neelima Sinha

Sanjeev Anant Kulkarni

Navnath Popat Karche

Manojkumar Ramprasad Shukla

Anil Kashiram Hajare

Prathap Sreedharan Nair

Nageswara Rao Irlapati

Mahadeo Bhaskar Tryambake

Samiron Phukan

Gokul Keruji Deshmukh

Milind Dattatraya Sindkhedkar

Bhavesh Dave

Rakesh Kumar Banerjee

Abhijit Datta Khoje

Rajkumar Hangarge

Chetan Sanjay Pawar

Jitendra Sambhaji Jadhav

Ankush Gangaram Sarde

Vijay Pandurang Karche

Ajay Ramchandra Tilekar

Vidya Ramdas

Gourhari Jana

Chaitanya Prabhakar Kulkarni

Rajeshkumar Maganlal Loriya

Ganesh Bhausaheb Gudade

Talha Hussain Khan

Navnath Bajirao Walke

Amit Kumar Das

Dipak Raychand Lagad

Deepak Sahebrao Walke

Shridhar Keshav Adurkar

Vinod Dinkar Chaudhari

Ramesh Dattatraya Phadtare

Sachin Sethi

Santosh Madhukar Jachak

Vipul Dilip Pachpute

Sanjay Pralhad Kurhade

Majid Bashir Sayyed

Nilesh Raghunath Khedkar

Advait Arun Joshi

Moloy Manoj Banerjee

Zubair Abdul Wajid Shaikh

Baban Rupaji Thube

Dnyaneshwar Changdeo Bhanage

Rajan Goel

Balasaheb Arjun Gore

Nirmal Kumar Jana

Kumar Ram Naik

Bhavani Shankar Rajesh

Dronamraju Prameela

Kamlesh Jyotindra Padiya

Pradeep Rangrao Patil

Sachin Jaysing Mahangare

Prashant Popatrao Vidhate

Sachchidanand Sachchidanand

Ganesh Navinchandra Gote

Kiran Chandrashekhar Kulkarni

Vaibhav Madhukar Kalhapure

Sudershan Kumar Arora

Rajesh Thotapally

Gagan Kukreja

Sapana Suresh Patel

Amolsing Dattu Patil

Seema Prabhakar Zade

Rohan Mahadev Shinde

Onkar Gangaram Kachi

Atish Harishchandra Rodge

Ashok Bhau Pathak

Bhavana Shrirang Kardile

Girish Dhanraj Hatnapure

Nabendu Saha

Sai Kumar Chakka

Azmi Reddy

Pravin Patil

K H Sreedhara Swamy

Kamalakannan Prabakaran

Subhash Ingawale Sachin

Sarde Gangaram Ankush

Shankar Dange Santoshkumar

Laxmikant Shamlal Datrange

Pachpute Dilip Vipul

Barve Sitaram Rambhau

Spinvin Venugopal

Ganpati Powar Rajendra

Dattatray Karche Amit

Sachin Subhash Ingawale

Rajendra Ganpati Powar

Dagadu Dube

Anand Jagannath Tarage

Vikas Sitaram Tambe

Prabakaran Kamalakannan

Bikramjit Singh Lairikyengbam

Firoj Aftab Raje

Arun Rangnath Jagdale

Ravindra Babanrao Jape

Rahul Shripad Nandurdikar

Sachin Madan

Prashant Vitthalrao Tale

Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.

Macrocyclic compounds as sting agonists and methods and uses thereof

This disclosure relates to pharmaceutical combinations for treating and/or preventing cancer and methods and uses thereof. More particularly, provided are pharmaceutical combination comprising a PRMT5 Inhibitor and a cellular activity modulator selected from an EGFR inhibitor, a KRAS inhibitor, a KRAS-G12C inhibitor, a MEK inhibitor, a Bcl-2 inhibitor, a SOS1 inhibitor, a PARP inhibitor, a RAF inhibitor, a ERK inhibitor, a CDK4/6 inhibitor, a MALT1 inhibitor, a BTK inhibitor, MAT2A inhibitor, a PI3K inhibitor, a AKT inhibitor, a FGFR inhibitor, a Type I PRMT inhibitor, a STING agonist, or an immune checkpoint inhibitor/modulator.

Pharmaceutical combination of PRMT5 inhibitors

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Formula (I) wherein, ring A, Rto R, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

Substituted tricyclic compounds

A process for manufacturing substituted chroman compounds in an economically scalable manner, without the use of pyrophoric reagents. Also disclosed herein are chroman compound synthesis routes that do not include column chromatography purification steps. The disclosure also relates to the intermediates used in the synthesis. In particular, the disclosure relates to the synthesis of the Calcium sensing receptor (CaSR) modulating agent 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates and pharmaceutically acceptable salts thereof.

Process for preparing chroman compounds

The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

PRMT5 inhibitors

This disclosure describes an economical and scalable method and process to synthesize the Calcium sensing receptor (CaSR) modulating agent 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates and pharmaceutically acceptable salts therefor. Uses of said intermediates for synthesis of compounds which may be intermediates to the synthesis of 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid are also described herein.

Methods, processes and intermediates for preparing chroman compounds

The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors

The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

Oxazoline and isoxazoline derivatives as CRAC modulators

The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly Na1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly Na1.7. The invention also relates to process for the preparation of the compounds of the invention. 

Sulfonamide compounds as voltage-gated sodium channel modulators

The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. 

Substituted chroman compounds as calcium sensing receptor modulators

The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment. The compounds as disclosed herein are of Formula (I) below: 

Heterocyclyl compounds as MEK inhibitors

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R-R, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject. 

Quinolizinone derivatives as PI3K inhibitors

The present invention is related to heteroaryl compounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them. 

Heterocyclyl compounds

The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators.

Chromane and chromene derivatives and their use as CRAC modulators

Growing community of inventors

Pune, India

Rajender Kumar Kamboj